We next determined the potency of CAR‐T cells by IFN‐γ release assay when CAR‐T effector cells were co‐cultured with two different IL‐13Rα2 positive target glioma tumour cell lines (U251 and U87MG) and one IL‐13Rα2 negative glioma cell line (T98G). The gene discussed is IFNG; the disease is central nervous system cancer.